HCM
GYRE icon

Highbridge Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Highbridge Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-27
Closed -$89K – 1378
2013
Q2 		$89K Buy
+27
New +$103K ﹤0.01% 1242

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Highbridge Capital Management's GYRE Position: Q3 2013 in Review

Highbridge Capital Management sold out of Gyre Therapeutics (GYRE) in Q3 2013, closing a stake of 27 shares — an estimated $89K sold.

Highbridge Capital Management first reported a position in GYRE in Q2 2013 and held it in 1 quarter. The position peaked at $89K in Q2 2013. 74 funds tracked by Wall St. Rank hold GYRE as of Q3 2013.

  • Highbridge Capital Management reported no remaining Gyre Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Highbridge Capital Management sold 27 Gyre Therapeutics shares in Q3 2013, an estimated $89K.
  • Highbridge Capital Management first reported a position in Gyre Therapeutics in Q2 2013 and held it in 1 quarter.
  • Highbridge Capital Management's Gyre Therapeutics position peaked at $89K in Q2 2013.
  • 74 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2013.

Based on Highbridge Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.